The History of Peptide Research: A Timeline

Emil Fischer — already the architect of sugar and purine chemistry — turns to proteins and, with Ernest Fourneau, synthesizes glycyl-glycine: two amino acids joined by what he names the peptide bond, coining "peptide" itself (from peptos, digested). Fischer's program is audacious for its era: he argues proteins are not colloidal mysteries but molecules — chains of amino acids in definite linkage — and by 1907 he has built an 18-residue chain by hand, a heroic feat with the tools of the time. The bond he named turns out to be the entire backbone of biology.

Frederick Banting, Charles Best, J.J.R. Macleod, and James Collip isolate insulin — and within months it is saving lives. Beyond its medical drama, insulin settles a scientific question: polypeptides are not just structural material; they are messages, potent at astonishingly small quantities. The molecule becomes the field's reference object for the next forty years — the thing everyone sequences, synthesizes, and engineers first.

Two converging revolutions. Linus Pauling, Robert Corey, and Herman Branson publish the α-helix and β-sheet, deducing from the peptide bond's planar geometry how backbones must fold. And Frederick Sanger, in a decade-long tour de force, determines insulin's complete amino-acid sequence — the first protein ever sequenced — proving that a protein is one exact, defined order of residues, not a statistical blend (Sanger F. Annu Rev Biochem. 1988;57:1–28). It is difficult to overstate what this licenses: if sequence is definite, then sequence can be written down, calculated from, and manufactured to — the premise of every identity test and every entry in a modern compound table.

Vincent du Vigneaud sequences and then synthesizes oxytocin — nine residues, a disulfide ring — the first peptide hormone built entirely by chemistry, indistinguishable from the natural molecule. The demonstration lands the 1955 Nobel Prize and establishes the field's central article of faith: a synthetic peptide with the natural sequence is the natural molecule.

R. Bruce Merrifield publishes solid-phase peptide synthesis — anchor the chain to a resin bead, and assembly becomes a repeatable cycle rather than a bespoke campaign (Merrifield RB. Science. 1965;150(3693):178–185). What took du Vigneaud's laboratory years becomes, eventually, what a machine runs overnight. Recognized with the 1984 Nobel Prize, SPPS remains, with refinements, how essentially every research peptide is made today — and its characteristic imperfections (deletion sequences, the compounding arithmetic of coupling yield) remain what analytical methods exist to measure.

Roger Guillemin and Andrew Schally — in one of science's most famous rivalries — isolate the hypothalamic releasing hormones: TRH, GnRH, somatostatin, and the lineage that leads to GHRH. The work requires processing literal tons of tissue to recover milligrams of peptide, and it proves that tiny peptides sitting atop endocrine axes control the body's major signaling cascades. The 1977 Nobel Prize follows. Every GHRH-analogue article in this library is downstream of this decade — the natural sequences that later engineering would edit.

With synthesis routine, the question inverts: not can we make nature's sequence but can we improve it. The answer arrives quickly — 1980 brings [Nle⁴, D-Phe⁷]-α-MSH, a melanocortin analogue more potent and more stable than its parent, an early landmark of deliberate stability engineering: unnatural residues, D-amino acids, terminal caps, cyclization. The design vocabulary that fills a modern catalog — every substitution with a rationale — is this decade's invention.

Molecular cloning identifies, one by one, the proteins peptides had been talking to all along: the melanocortin receptor family, the GLP-1 receptor, the growth-hormone-secretagogue receptor GHS-R1a — each cloning a small revolution, because a cloned receptor means recombinant cell lines, attributable assays, and the modern characterization vocabulary of EC50, selectivity, and efficacy. Pharmacology shifts from measuring effects in tissues to measuring mechanisms at named receptors — the evidentiary standard every comparison article in this library is written to.

Structural biology catches the receptors in the act: Brian Kobilka and Robert Lefkowitz's work on GPCR structure and function — crowned by crystal structures of receptors mid-signal — earns the 2012 Nobel Prize and converts receptor pharmacology from inference to observation (Rosenbaum DM, Rasmussen SG, Kobilka BK. Nature. 2009;459(7245):356–363). Concepts this library leans on constantly — conformational states, biased agonism, the class B two-domain binding mode that accommodates long peptide ligands — become literal, visible geometry.

The current era's signature is designed polypharmacology: single peptides engineered to engage defined sets of receptors with tuned ratios — the single-, dual-, and triple-agonist progression detailed in the incretin comparison — alongside half-life engineering by lipidation and albumin-binding chemistry. A century after Fischer joined two glycines, peptide science writes sequences nature never did, with receptor profiles chosen in advance — and verifies them with mass spectrometers that read the molecular weight Sanger's revolution made calculable.

Because every convention in modern documentation is a hard-won historical answer. Sequences are stated exactly because Sanger proved they are exact. Synthetic material is treated as equivalent to natural because du Vigneaud demonstrated it. Purity is measured because Merrifield's method has characteristic imperfections. Receptor claims cite EC50s at named receptors because the cloning era made mechanisms attributable. A Certificate of Analysis is, in a real sense, the field's whole history compressed onto one page — and reading this library with the timeline in mind is reading a century of ideas, still in active use.